Edition:
United Kingdom

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

1.36USD
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
$1.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
29,277
52-wk High
$3.33
52-wk Low
$1.31

Latest Key Developments (Source: Significant Developments)

Moleculin Targets Accelerated FDA Approval Of Wp1732 Pursues Development For Ocular Tumors
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Moleculin Biotech Inc ::MOLECULIN TARGETS ACCELERATED FDA APPROVAL OF WP1732; PURSUES DEVELOPMENT FOR OCULAR TUMORS.  Full Article

Moleculin Biotech Reports Q1 Loss Per Share Of $0.08
Tuesday, 15 May 2018 

May 15 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH INC REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2018.MOLECULIN BIOTECH INC- QTRLY LOSS PER SHARE $0.08.MOLECULIN BIOTECH - BELIEVES THAT EXISTING CASH AND CASH EQUIVALENTS AS OF MARCH 31, WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO Q1 2019.MOLECULIN BIOTECH INC - AS OF MARCH 31, 2018, COMPANY HAD $13.1 MILLION IN CASH AND CASH EQUIVALENTS.  Full Article

Moleculin Biotech Resale By Selling Shareholders Of Up To 2.1 Mln Shares Of Co's Common Stock Issuable Upon Exercise Of Outstanding Warrants
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Moleculin Biotech Inc ::RESALE BY SELLING SHAREHOLDERS OF UP TO 2.1 MILLION SHARES OF CO'S COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS.  Full Article

Moleculin Announces Polish Approval For Leukemia Clinical Trial
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Moleculin Biotech Inc ::MOLECULIN ANNOUNCES POLISH APPROVAL FOR LEUKEMIA CLINICAL TRIAL.MOLECULIN BIOTECH - ETHICS COMMITTEE IN POLAND HAS APPROVED COMPANY'S PHASE I/II CLINICAL TRIAL OF ANNAMYCIN FOR TREATMENT OF LEUKEMIA.MOLECULIN BIOTECH INC - COMPANY EXPECTS FIRST PATIENT TO BE ENROLLED IN Q1 2018.MOLECULIN BIOTECH - BELIEVES CLINICAL DATA PRODUCED IN POLAND WILL BE USEFUL IN INTERACTIONS WITH U.S. FDA, EUROPEAN MEDICINES AGENCY.  Full Article

Moleculin's WP1066 Drug Gets FDA Brain Tumor IND Clearance
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Moleculin Biotech Inc ::MOLECULIN'S WP1066 DRUG GETS FDA BRAIN TUMOR IND CLEARANCE.MOLECULIN BIOTECH-IND APPLICATION FOR PHASE I TRIAL OF WP1066 IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA, BRAIN METASTASIS FROM MELANOMA, ALLOWED BY FDA.  Full Article

Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Moleculin Biotech Inc ::MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING.  Full Article

Moleculin Biotech Q3 loss per share $0.14‍​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Moleculin Biotech Inc : :Moleculin Biotech Inc reports financial results for the third quarter ended september 30, 2017.Moleculin Biotech Inc - qtrly loss per share $0.14‍​.  Full Article

Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Moleculin Biotech Inc :Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors.Moleculin-Responses to FDA requests for more information regarding physician-sponsored ind for WP1066 as potential treatment for brain tumors submitted​.  Full Article

Moleculin requests for clinical trial authorization to study annamycin
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Moleculin Biotech Inc ::Moleculin Biotech - ‍submitted request for clinical trial authorization to study annamycin for treating relapsed/refractory acute myeloid leukemia in Poland.  Full Article

Moleculin announces strategic collaboration to develop immune stimulation drug
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Moleculin Biotech Inc ::Moleculin announces strategic collaboration to develop immune stimulation drug.Moleculin Biotech - ‍entered into an agreement to collaborate with University of Bergen to expand research on inhibition of brain metastasis by moleculin's pre-clinical drug WP1066​.Moleculin biotech - ‍Moleculin anticipates clinical trial for drug to be ready to begin by end of this year​.Moleculin Biotech - investigational new drug ‍application to study WP1066 ‍in patients with glioblastoma and melanoma has been on hold pending responses to requests from FDA​.Moleculin Biotech - ‍anticipates clinical trial on WP1066 to begin by end of the year. If FDA allows the IND application to proceed based on responses provided​.  Full Article